GSBR-1290

GSBR-1290 is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. On 18 December 2023 trial results failed to meet exceptions and Structure Therapeutics share price lost half its value.